Jasper Therapeutics JSPR

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company engaged in the discovery and development of therapeutics that target mast cell driven diseases. The company's lead product candidate, briquimimab, is a monoclonal antibody designed to block stem cell factor from binding to the KIT receptor on mast cells, thereby depleting these immune cells and modulating the underlying disease process. Jasper Therapeutics is advancing briquimimab through clinical trials for chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma, while also evaluating additional mast cell driven indications for future development.

As a clinical-stage entity, Jasper Therapeutics does not yet generate revenue from product sales. Its current revenue stream consists of milestone payments, potential royalties, and research support received under licensing agreements, most notably its exclusive worldwide license with Amgen for briquimimab, which includes access to supplied drug material for clinical trials. The company also holds an exclusive license with Stanford University related to intellectual property for stem cell depletion, which may yield additional financial considerations. Furthermore, Jasper Therapeutics may receive funding from collaborations or grants that support its research and development activities.

Jasper Therapeutics operates in a competitive biotechnology landscape where multiple companies pursue therapies that modulate mast cell activity. Direct competitors working on KIT targeted approaches include Celldex Therapeutics, which is developing an antibody that targets KIT, and Blueprint Medicines, which is advancing a small molecule KIT inhibitor. Other firms addressing mast cell mediated diseases with different mechanisms are Novartis (BTK inhibitor), Sanofi (interleukin 4 receptor alpha antibody), and Evommune (MRGPRX2 antagonist). The market opportunity is substantial, as chronic spontaneous urticaria is estimated to affect over five million patients in the United States, France, Germany, Italy, Spain, and the United Kingdom, while chronic inducible urticaria affects over two million patients in those same regions. Jasper Therapeutics differentiates itself through its exclusive worldwide license with Amgen for briquimimab, a robust patent portfolio covering the KIT antibody and related technologies, and its clinical focus on depleting mast cells rather than merely blocking symptomatic pathways.

Although Jasper Therapeutics has not yet commercialized a product, its intended customers are patients diagnosed with mast cell driven diseases such as chronic spontaneous urticaria, chronic inducible urticaria, and asthma. The company also anticipates that healthcare providers who treat these conditions, including dermatologists, allergists, and pulmonologists, will be key stakeholders in any future commercialization. Jasper Therapeutics aims to make its therapies available in the American, European, and Japanese markets, focusing on physicians who prescribe the majority of mast cell directed treatments.